HC Wainwright Has Optimistic Outlook of COLL Q3 Earnings

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Investment analysts at HC Wainwright upped their Q3 2025 earnings estimates for Collegium Pharmaceutical in a research note issued to investors on Monday, March 24th. HC Wainwright analyst O. Livnat now forecasts that the specialty pharmaceutical company will earn $1.75 per share for the quarter, up from their previous forecast of $1.61. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $5.62 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q4 2025 earnings at $1.82 EPS, FY2025 earnings at $6.26 EPS and FY2026 earnings at $6.36 EPS.

Other research analysts have also issued reports about the stock. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research note on Friday, January 10th. Piper Sandler lowered their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Stock Performance

Shares of Collegium Pharmaceutical stock opened at $29.56 on Thursday. The firm’s fifty day simple moving average is $30.43 and its 200-day simple moving average is $32.50. Collegium Pharmaceutical has a 12 month low of $27.28 and a 12 month high of $42.29. The stock has a market capitalization of $930.73 million, a price-to-earnings ratio of 12.74 and a beta of 0.99. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 2,255 shares of the business’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the sale, the executive vice president now directly owns 124,421 shares in the company, valued at approximately $3,732,630. The trade was a 1.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the transaction, the executive vice president now owns 119,184 shares of the company’s stock, valued at $3,937,839.36. This represents a 18.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 109,193 shares of company stock worth $3,243,594 over the last ninety days. 3.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. New Age Alpha Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at approximately $40,000. TD Private Client Wealth LLC raised its holdings in Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares during the last quarter. KBC Group NV raised its holdings in Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 982 shares during the last quarter. Virtus Fund Advisers LLC boosted its position in Collegium Pharmaceutical by 30.5% during the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 565 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 316 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.